Research programme: antibacterials - Glykoz

Drug Profile

Research programme: antibacterials - Glykoz

Latest Information Update: 19 Jan 2011

Price : $50

At a glance

  • Originator Glykoz
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 25 Sep 2005 This programme is still in active development at the lead optimisation stage - BIO-2005 Annual International Convention (BIO-2005)
  • 26 Jul 2004 Optimisation and preclinical trials in Bacterial infections (unspecified route)
  • 26 Jul 2004 Compounds resulting from this discovery and development programme are available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top